Targeting the tumor microenvironment with SRC kinase inhibition

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alicia S Chung, Napoleone Ferrara

Abstract

Although most cancer therapies are directed against tumor cells, an emerging area of cancer therapeutics focuses on targeting cells of the tumor microenvironment. Inhibiting the Src family kinase with dasatinib decreases tumor growth through inhibiting growth of tumor-associated endothelial and myeloid cells.

Citations

Dec 2, 2011·Clinical & Experimental Metastasis·Lori RiceDietmar W Siemann
Mar 12, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Bo ZhangShao Li
Mar 31, 2015·ACS Medicinal Chemistry Letters·Emilia PăunescuPaul J Dyson
Jul 1, 2020·Experimental Biology and Medicine·Sukanya RoySanjukta Chakraborty
Aug 27, 2021·Current Oncology·Terence Teixeira DuarteRui Manuel Reis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.